News
The Australian company offers its members access to AI agents that analyze their health data, lifelong health plans, whole-body testing and a personal doctor.
The funds will be used to grow the company's engineering and commercial workforce, enhance product development, and accelerate integration with payers and providers.
The company will utilize the funds to accelerate the development of its clinical diagnostic platform and expand its partnerships with pharmaceutical and biotechnology firms.
The company offers mail-in semen analysis and vasectomy testing.
The FDA claims the wearable tech company's BPI offering is "adulterated" and "misbranded," and is being sold without the proper regulatory approvals.
The new firm will offer partners an expanded range of methods and workflows for small-molecule and peptide drug discovery.
Hippocratic AI will integrate its generative AI agents to support triage and patient intake.
Patients will have 24/7 access to personalized speech, language and cognitive therapies.
The company will use the funds to augment key content partnerships.
Arnaub Chatterjee, Datavant president and GM of life sciences, says the company will streamline data linking and evidence generation across real-world and clinical trial data.